| Billie Jo H Cornett, CNM | |
|
8901 W Lincoln Ave Ste 411, West Allis, WI 53227-2409 | |
| (414) 328-6000 | |
| (414) 328-8536 |
| Full Name | Billie Jo H Cornett |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 8901 W Lincoln Ave Ste 411, West Allis, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326527425 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 148955 (Wisconsin) | Primary |
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Researchers have successfully used a peptide to reverse biochemical, cellular and anatomical changes that occur in the brains of mice with Parkinson's disease (PD), and report success in preventing the disease from progression.
The United States regulator, Food and Drugs Administrator (FDA) has approved a machine called the Artas System for commercial use. According to manufacturers Restoration Robotics, Artas is "an interactive, computer assisted system utilizing image-guided robotics to enhance the quality of hair follicle harvesting" by combining "several features including an interactive, image-guided robotic arm, special imaging technologies, small dermal punches and a computer interface." Artas can be used only on patients with straight brown or black hair at this stage.
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.
Ontario Shores Centre for Mental Health Sciences (Ontario Shores) is creating a new public website intended to better serve the needs of users and provide opportunities to engage in online dialogue with a variety of stakeholders.
The findings of a polysomnography study have strengthened the link between rapid eye movement sleep behavior disorder and Parkinson's disease, suggesting that it is specifically associated with freezing of gait.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Billie Jo H Cornett, CNM 8901 W Lincoln Ave Ste 411, West Allis, WI 53227-2409 Ph: (414) 328-6000 | Billie Jo H Cornett, CNM 8901 W Lincoln Ave Ste 411, West Allis, WI 53227-2409 Ph: (414) 328-6000 |
News Archive
Researchers have successfully used a peptide to reverse biochemical, cellular and anatomical changes that occur in the brains of mice with Parkinson's disease (PD), and report success in preventing the disease from progression.
The United States regulator, Food and Drugs Administrator (FDA) has approved a machine called the Artas System for commercial use. According to manufacturers Restoration Robotics, Artas is "an interactive, computer assisted system utilizing image-guided robotics to enhance the quality of hair follicle harvesting" by combining "several features including an interactive, image-guided robotic arm, special imaging technologies, small dermal punches and a computer interface." Artas can be used only on patients with straight brown or black hair at this stage.
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.
Ontario Shores Centre for Mental Health Sciences (Ontario Shores) is creating a new public website intended to better serve the needs of users and provide opportunities to engage in online dialogue with a variety of stakeholders.
The findings of a polysomnography study have strengthened the link between rapid eye movement sleep behavior disorder and Parkinson's disease, suggesting that it is specifically associated with freezing of gait.
› Verified 4 days ago
Jessica N Schaefer, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 8905 W Lincoln Ave Ste 515, West Allis, WI 53227 Phone: 414-328-8650 | |
Cheryl Ann Jaeger, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 8905 W Lincoln Ave, Suite 515, West Allis, WI 53227 Phone: 414-328-8650 Fax: 414-328-8660 | |
Amanda Kliber, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 8905 W Lincoln Ave, Suite 501, West Allis, WI 53227 Phone: 414-978-2229 | |
Janet Gruner, RN CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 8905 W Lincoln Ave, Suite 501, West Allis, WI 53227 Phone: 414-978-2229 Fax: 414-978-2279 | |
Lindsay K Gardner, CNM, MSN, RN Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Hannah C Holena, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2239 S 108th St, West Allis, WI 53227 Phone: 414-541-2772 |